BioAgilytix Named 2025 Fast 50 Award Recipient by Triangle Business Journal

Continued recognition reflects sustained growth and leadership in bioanalytical excellence

Durham, N.C. — November 1, 2025— BioAgilytix, the global leader in bioanalysis, has been named a recipient of Triangle Business Journal’s Fast 50 award for 2025, marking the company’s 13th appearance on the prestigious list and recognition for its growth and leadership. 

The Fast 50 Awards recognize the Triangle’s fastest-growing privately held companies based on a combination of revenue growth and profitability over the past three years. BioAgilytix’s continued inclusion on this list underscores its strong financial performance and strategic expansion across the U.S., Europe, and Australia. 

“BioAgilytix is honored to be recognized for the growth and excellence produced by our people, our science, and our partnerships,” said Davide Molho, CEO of BioAgilytix. “Our team’s commitment to quality and innovation drives our growth and enables us to make a real difference for our customers and the patients they serve.” 

In the past year, BioAgilytix has made significant investments to strengthen its global bioanalytical capabilities, including the expansion of its labs in North Carolina, Europe, and Australia, the appointment of new leaders across technology and growth functions, and continued advancements in scientific platforms supporting preclinical through phase 3 development. 

Headquartered in Durham, NC, BioAgilytix continues to be a key contributor to the Research Triangle’s thriving life sciences ecosystem. The company employs over 1,100 dedicated team members and scientists globally, and maintains a strong commitment to fostering innovation, career growth, and community engagement. 

About BioAgilytix 

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.